224824-22-0

Usage

Uses

Used in Organic Synthesis:
(S)-(4-(2-((tert-Butoxycarbonyl)aMino)-3-Methoxy-3-oxopropyl)phenyl)boronic acid is used as a synthetic intermediate for the preparation of various organic compounds. Its boronic acid functionality allows for the formation of reversible covalent bonds with diols, facilitating the synthesis of complex organic molecules.
Used in Medicinal Chemistry:
In the pharmaceutical industry, (S)-(4-(2-((tert-Butoxycarbonyl)aMino)-3-Methoxy-3-oxopropyl)phenyl)boronic acid is used as a building block for the development of new drugs. The presence of the Boc-protected amino group and the methoxyoxopropyl group may provide specific reactivity or biological activity, making it a valuable component in the design of novel therapeutic agents.
Used in Chemical Research:
(S)-(4-(2-((tert-Butoxycarbonyl)aMino)-3-Methoxy-3-oxopropyl)phenyl)boronic acid is utilized as a research tool in chemical studies. Its unique structural features and potential reactivity make it an interesting subject for investigations into new reaction mechanisms, catalysts, or other applications in chemical science.
Used in Biological Research:
In the field of biology, (S)-(4-(2-((tert-Butoxycarbonyl)aMino)-3-Methoxy-3-oxopropyl)phenyl)boronic acid may be employed as a probe or modifier of biological systems. Its potential interactions with biological molecules could be explored for applications in understanding cellular processes or developing new biological assays.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 177797-94-3 L-H-Phe(4-B(OH)2)-OMe 
• 119771-23-2 N-(tert-butoxycarbonyl)-4-(dihydroxyboryl)-1-phenylalanine 
• 74-88-4 methyl iodide 
• 112766-18-4 methyl N-(tert-butoxycarbonyl)-O-[(trifluoromethyl)sulfonyl]-L-tyrosinate 
• 4326-36-7 (S)-N-(tert-butoxycarbonyl)tyrosine methyl ester 
• 220587-29-1 methyl (S)-2-((tert-butoxycarbonyl)amino)-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propanoate 
• 76410-58-7 p-borono-L-phenylalanine 

Downstream Products

• 632297-54-2 methyl N-(tert-butyloxycarbonyl)-4-(1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrazol-5-yl)-L-phenylalaninate 
• 632333-29-0 methyl N-(tert-butyloxycarbonyl)-4-pyrimidin-5-yl-L-phenylalaninate 
• 156017-43-5 (2S)-{4-[2-tert-butoxycarbonylamino-2-(methoxycarbonyl)-ethyl]-phenyl}difluoromethyl-phosphonic acid diethyl ester 
• 401906-12-5 methyl N-(tert-butoxycarbonyl)-4-(3-methyl-2,6-dioxo-3,6-dihydropyrimidine-1(2H)-yl)-L-phenylalaninate 
• 632297-68-8 methyl N-(tert-butyloxycarbonyl)-4-(1-trityl-1H-pyrazol-4-yl)-L-phenylalaninate 
• 632297-47-3 methyl N-(tert-butyloxycarbonyl)-4-(1H-pyrazol-1-yl)-L-phenylalaninate 
• 412024-58-9 N-(tert-butoxycarbonyl)-4-{1,3-bis(tert-butoxycarbonyl)-3-[2-(trimethylsilyl)ethoxymethyl]}amidino-L-phenylalanine, methyl ester 
• 193410-66-1 methyl N-[(1,1-dimethylethoxy)carbonyl]-O-[S]-[5-({[2-(1,1-dimethylethoxy)carbonyl]amino}-2-[(phenylmethoxy)carbonyl]ethyl)-2-(phenylmethoxy)phenyl]-L-tyrosinate 

Relevant academic research and scientific papers

SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF

Provided is a sulfonamide derivative represented by the following general formula (1) and having an α4 integrin inhibitory effect with high selectivity with a low effect on α4β1 and a high effect on α4β7, or a pharmaceutically acceptable salt thereof (in the general formula (1), A, B, D, E, R41, and a to h are as described in the description).

SULFONAMIDE DERIVATIVES AND PHARMACEUTICAL APPLICATIONS THEREOF

PROBLEM TO BE SOLVED: To provide novel compounds having excellent α4 integrin inhibitory action. SOLUTION: The invention relates to sulfonamide derivatives represented by the general formula (I) in the figure, or pharmaceutically acceptable salts thereof, or prodrugs thereof. (In the formula, a, b, c, d, D, E, R11, B, e, f, g, h and W are as defined herein.) SELECTED DRAWING: None COPYRIGHT: (C)2016,JPOandINPIT

SULFONAMIDE DERIVATIVE AND MEDICINAL USE THEREOF

Provided are sulfonamide derivatives of a specific chemical structure in which a sulfonamide group having, as a substituent, a phenyl group or a heterocyclic group having a hetero atom(s) as a constituent element(s) is present at its terminal, and pharmaceutically acceptable salts thereof. These compounds are novel compounds having excellent α4 integrin-inhibitory action.

A universal procedure for the [18F]trifluoromethylation of aryl iodides and aryl boronic acids with highly improved specific activity

Herein we describe a valuable method for the introduction of the [18F]CF3 group into arenes with highly improved specific activity by the reaction of [18F]trifluoromethane with aryl iodides or aryl boronic acids. This [su

Palladium-catalyzed difluoroalkylation of aryl boronic acids: A new method for the synthesis of aryldifluoromethylated phosphonates and carboxylic acid derivatives

The palladium-catalyzed difluoroalkylation of aryl boronic acids with bromodifluoromethylphosphonate, bromodifluoroacetate, and further derivatives has been developed. This method provides a facile and useful access to a series of functionalized difluoromethylated arenes (ArCF2PO(OEt) 2, ArCF2CO2Et, and ArCF2CONR 1R2) that have important applications in drug discovery and development. Preliminary mechanistic studies reveal that a single electron transfer (SET) pathway may be involved in the catalytic cycle. Palladium does it: The palladium-catalyzed difluoroalkylation of aryl boronic acids with bromodifluoromethylphosphonate, bromodifluoroacetate, and further derivatives has been developed (see scheme). Preliminary mechanistic studies reveal that a single electron transfer (SET) pathway may be involved in the catalytic cycle. Copyright

A new catalytic cross-coupling approach for the synthesis of protected aryl and heteroaryl amidines

(equation presented) A new method for the synthesis of protected benzamidines is described. The commercially available 1,3-bis(tert-butoxycarbonyl)-2-methyl-2-thiopseudourea guanidylation reagent, after SEM-protection, functions as an amidine-forming cros